Valneva announced it has voluntarily withdrawn its U.S. submissions for Ixchiq, its chikungunya vaccine, after the FDA placed a clinical hold on a post‑marketing study following a newly reported serious adverse event outside the U.S. Ixchiq received accelerated approval in November 2023 but has faced safety scrutiny, labeling changes and a suspended U.S. license last year. Regulators in Europe previously paused use in older adults amid severe adverse event reports; Valneva said the latest event involved concurrent administration of three vaccines and causality is undetermined. The company intends to continue post‑marketing activities subject to regulator discussions but removed the U.S. filing amid ongoing safety questions.